Leerink Partnrs Forecasts Beta Bionics FY2024 Earnings

Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) - Stock analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Beta Bionics in a note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per share of ($1.66) for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics' Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.95) EPS.

BBNX has been the topic of a number of other reports. Baird R W raised Beta Bionics to a "hold" rating in a research note on Thursday, February 20th. Bank of America assumed coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating on the stock. LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Lake Street Capital assumed coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating and a $25.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Beta Bionics currently has an average rating of "Moderate Buy" and a consensus target price of $24.83.

Remove Ads

Beta Bionics Stock Up 5.3 %

Beta Bionics stock traded up $1.06 during trading hours on Wednesday, reaching $20.97. The company had a trading volume of 294,220 shares, compared to its average volume of 330,311. Beta Bionics has a 12-month low of $18.67 and a 12-month high of $24.50.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger purchased 33,350 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the transaction, the insider now directly owns 59,019 shares of the company's stock, valued at $1,003,323. This trade represents a 129.92 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares of the company's stock, valued at $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.